ArticleFrontiers in immunology2026
Angiogenic markers in difficult-to-treat psoriatic arthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Difficult-to-treat (DTT) psoriatic arthritis (PsA) is characterized by persistent disease activity despite treatment with multiple advanced therapies. Angiogenesis and extracellular matrix remodeling are key processes in chronic inflammatory arthritis, with CD147 acting as an important regulator. Objective: Our aim was to evaluate the circulating pro- and anti-angiogenic mediators and inflammatory cytokines in patients with DTT PsA compared with non-DTT PsA controls. Methods and results: Serum samples from 22 patients with DTT PsA were compared with matched samples from 25 non-DTT PsA patients who were on biologics or targeted therapies (non-DTT Bio) and with 25 non-DTT PsA patients who were naive to biologics and targeted therapies and received conventional disease-modifying antirheumatic drugs (cDMARDs) or non-steroidal anti-inflammatory drugs (NSAIDs) (non-DTT cDMARDs). The concentrations of angiogenic factors and inflammatory cytokines were determined with ELISA. Compared with both control groups, patients with DTT PsA demonstrated significantly higher serum levels of CD147 and increased activities of MMP-9 and proteasome 20S, which were measured by the cleavage of their respective fluorescent substrates. The levels of vascular endothelial growth factor (VEGF), TIMP-1, endostatin, and thrombospondin-1 (Tsp-1) did not differ significantly. The scratch assay with diluted serum samples, which was used to measure the ability of endothelial cells to migrate and close the gap, revealed enhanced angiogenic potential in the DTT group relative to the two control groups. In contrast, no differences between the groups were revealed in the serum levels of IL-17, IL-23, IL-22, IL-6, TNF-α, and TGF-β, and only IL-12p70 was reduced in the DTT relative to the control groups. The CD147 levels increased over time exclusively in the DTT PsA group. Conclusions: An enhanced angiogenic profile, highlighted by an elevated CD147, was found in patients with DTT PsA compared with non-DTT patients, requiring further studies to better understand its role in the pathogenesis of and as a biomarker in PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.